# Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

> **NCT03474198** · PHASE2,PHASE3 · COMPLETED · sponsor: **University College, London** · enrollment: 675 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DRUG:** Linezolid
- **DRUG:** Clofazimine
- **DRUG:** Rifapentine
- **DRUG:** Levofloxacin
- **DRUG:** Bedaquiline
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT03474198
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2022-01-20
- **Final completion:** 2022-01-20
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474198, "Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03474198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*